DARAXONRASIB significantly extended overall survival versus chemotherapy in patients with refractory metastatic pancreatic cancer. Findings from the pivotal Phase 3 randomized clinical trial demonstrate that the first-in-class multi-selective RAS inhibitor provides substantial clinical benefit for patients with advanced disease who have experienced progression following initial chemotherapy. The trial evaluated the targeted therapeutic against standard second-line cytotoxic regimens across a diverse international patient population.
Pancreatic ductal adenocarcinoma remains one of the most lethal and treatment-resistant malignancies in clinical oncology, characterized by limited therapeutic alternatives and historically poor prognosis after frontline therapy failure. In this randomized investigation, patients receiving oral daraxonrasib achieved a median overall survival of 13.2 months, compared with 6.7 months among patients assigned to investigator-choice chemotherapy. This substantial survival gain corresponds to a 60% reduction in the risk of mortality.
Progression-free survival also demonstrated a pronounced and statistically significant advantage. Individuals in the daraxonrasib arm achieved a median progression-free survival of 7.2 months versus 3.6 months in the chemotherapy control group. Subgroup analyses confirmed consistent therapeutic efficacy across major oncogenic variants, including KRAS G12D, G12V, and G12R mutations, which together account for more than 90% of all RAS-driven pancreatic malignancies.
The targeted multi-selective inhibitor displayed a manageable toxicity profile relative to cytotoxic therapies. Grade 3 or higher treatment-related adverse events occurred in 61.8% of patients receiving daraxonrasib compared to 69.6% of patients assigned to chemotherapy. The most common adverse events observed with daraxonrasib were dermatologic rash, diarrhea, stomatitis, fatigue, and nausea, which clinicians managed through standard supportive interventions and protocol-defined dose modifications.
Treatment discontinuation due to drug-related toxicity was markedly lower in the daraxonrasib cohort at 1.2%, compared to 11.2% in the chemotherapy arm. By delivering a clinically meaningful survival extension alongside improved tolerability, daraxonrasib in metastatic pancreatic cancer represents a transformative targeted therapeutic strategy for patients requiring second-line disease management.
Reference
Wolpin BM et al. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. N Engl J Med. 2026.
Featured Image: cunaplus on Adobe Stock.
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
